KBC Group NV Has $213.32 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

KBC Group NV lifted its position in Johnson & Johnson (NYSE:JNJ) by 26.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,320,887 shares of the company’s stock after buying an additional 276,379 shares during the period. Johnson & Johnson comprises 0.8% of KBC Group NV’s holdings, making the stock its 21st largest position. KBC Group NV’s holdings in Johnson & Johnson were worth $213,323,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Biondo Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Biondo Investment Advisors LLC now owns 44,161 shares of the company’s stock worth $7,178,000 after buying an additional 785 shares during the last quarter. Private Advisor Group LLC lifted its stake in Johnson & Johnson by 55.8% in the 3rd quarter. Private Advisor Group LLC now owns 606,141 shares of the company’s stock valued at $97,893,000 after purchasing an additional 217,128 shares during the last quarter. Kathmere Capital Management LLC lifted its stake in Johnson & Johnson by 20.7% in the 3rd quarter. Kathmere Capital Management LLC now owns 6,262 shares of the company’s stock valued at $1,011,000 after purchasing an additional 1,074 shares during the last quarter. Cooke & Bieler LP lifted its stake in Johnson & Johnson by 3.9% in the 2nd quarter. Cooke & Bieler LP now owns 744,378 shares of the company’s stock valued at $122,629,000 after purchasing an additional 28,195 shares during the last quarter. Finally, 1900 Wealth Management LLC lifted its stake in Johnson & Johnson by 36.9% in the 3rd quarter. 1900 Wealth Management LLC now owns 7,646 shares of the company’s stock valued at $1,235,000 after purchasing an additional 2,059 shares during the last quarter. Institutional investors own 67.48% of the company’s stock.

In other news, CAO Robert J. Decker sold 5,000 shares of the business’s stock in a transaction dated Tuesday, December 7th. The shares were sold at an average price of $163.21, for a total transaction of $816,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.30% of the company’s stock.

Several research analysts have weighed in on JNJ shares. Raymond James lowered their price target on shares of Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating on the stock in a report on Wednesday, October 20th. The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a report on Friday, December 17th. They set a “neutral” rating and a $161.00 target price on the stock. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 target price on the stock in a report on Friday, October 22nd. Citigroup reaffirmed a “buy” rating and set a $195.00 target price (up from $192.00) on shares of Johnson & Johnson in a report on Wednesday, December 15th. Finally, Wells Fargo & Company reissued a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, October 7th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $186.00.

Johnson & Johnson stock traded up $0.34 during mid-day trading on Thursday, reaching $170.13. The company had a trading volume of 115,812 shares, compared to its average volume of 6,358,561. Johnson & Johnson has a fifty-two week low of $151.47 and a fifty-two week high of $179.92. The company has a current ratio of 1.34, a quick ratio of 1.11 and a debt-to-equity ratio of 0.43. The company has a market cap of $447.88 billion, a P/E ratio of 25.38, a P/E/G ratio of 2.38 and a beta of 0.74. The business has a fifty day simple moving average of $165.86 and a 200 day simple moving average of $167.39.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Monday, October 18th. The company reported $2.60 EPS for the quarter, topping analysts’ consensus estimates of $2.35 by $0.25. The company had revenue of $23.34 billion for the quarter, compared to analyst estimates of $23.72 billion. Johnson & Johnson had a net margin of 19.55% and a return on equity of 37.90%. Johnson & Johnson’s revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.20 earnings per share. Research analysts forecast that Johnson & Johnson will post 9.8 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 8th. Shareholders of record on Tuesday, February 22nd will be paid a $1.06 dividend. This represents a $4.24 annualized dividend and a yield of 2.49%. The ex-dividend date is Friday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 63.38%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Recommended Story: What is the Dividend Aristocrat Index?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.